XML 37 R30.htm IDEA: XBRL DOCUMENT v3.26.1
Collaboration Agreement with GSK - Additional Information (Details)
$ in Thousands
1 Months Ended 3 Months Ended
Aug. 17, 2021
USD ($)
Jul. 01, 2021
USD ($)
May 31, 2023
USD ($)
Jan. 31, 2022
USD ($)
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Research and development expense         $ 17,857 $ 33,641  
GlaxoSmithKline plc              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Effective date of agreement Aug. 17, 2021            
Upfront payments   $ 700,000     $ 700,000    
Milestone payment received $ 500,000     $ 200,000      
Percentage Of Development Cost         0.60    
Collaboration revenue         $ 1,000 3,700  
Deferred revenue         169,600   $ 171,200
Research and development expense         1,800 $ 4,300  
Transaction price         568,000    
Contract with customer, refund liability         0   $ 11,400
Maximum funding     $ 140,500        
GlaxoSmithKline plc | Maximum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Additional milestone payments related to initiation of certain clinical studies and regulatory approval         $ 1,500,000    
Alector              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Percentage Of Development Cost         0.40